Idorsia Pharmaceuticals Ltd. has identified aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor (HCRTR2) agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.